Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- PIII Study of Brexpiprazole Starts in US and Europe for Treatment of Agitation in AD: Otsuka Holdings
November 18, 2013
- Sales of Major Japanese Drug Makers Soar 8.1% on Weak Yen, Steady Japan Business
November 15, 2013
- Chugai Puts Off NHI Price Listing for Kadcyla, Agreement Not Reached
November 15, 2013
- Otsuka Holdings Notches Double-Digit Sales Growth in April-September, Weaker Yen Comes as Boon
November 14, 2013
- Chugai Obtains Exclusive Commercialization Rights for Anamorelin in Europe from Helsinn
November 14, 2013
- Kenko.com Sues Government to Affirm Right to Sell Prescription Drugs Online
November 14, 2013
- Generic Market Continues to Grow, Three Generic-Only Makers’ Sales Up 8.8%
November 13, 2013
- Kyowa Kirin Ceases Japan PII Trial on Chronic Kidney Disease Agent
November 13, 2013
- JV of DSP, Japan BCG to Develop New TB Vaccines with NIBIO, US NPO
November 13, 2013
- Antiepileptic Drug Eslicarbazepine Granted US Approval: DSP
November 13, 2013
- Commercial Director Feliciano to Become President of Merck Serono Japan
November 12, 2013
- Eylea Bests Lucentis in Ophthalmic VEGF Inhibitor Market; Santen Ups Sales Outlook for Drug
November 12, 2013
- GLP-1 Dulaglutide “Catalyst of Growth,” SGLT-2 Empagliflozin Will Be Successful Despite Later Launch: Lilly Diabetes President
November 12, 2013
- Ethical Drug Sales Up 5.3% in September: Crecon Report
November 12, 2013
- Eisai to Develop Belviq for Japan Market via Expanded Deal with Arena
November 12, 2013
- NCC, Sanofi Forge Alliance in Anticancer Drug R&D
November 12, 2013
- Eisai Enters Global Agreement with Broad Institute of US to Develop New Drugs for NTDs and Tuberculosis
November 12, 2013
- 4 Major Wholesalers’ Operating Margins Stay on Recovery Path, But Average Settlement Rate at Mere 72% at Sept.-End
November 11, 2013
- Nichi-Iko Pres. Airs Frustration with Sanofi over Cancellation of Biosimlar Codevelopment Deal
November 8, 2013
- Nichi-Iko Pitting Allegra AG against Other Generics, Not Originator: Pres. Tamura
November 8, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…